구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Gene Modified T Cells |
Overview Company | Calimmune, Inc. |
Overview Modality | CGT |
Overview Target | Prostate Cancer |
Overview Indication | Colorectal Cancer |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | viral vectors, CAR T cells were produced using the piggyBac transposon system of genetic mod |
MoA Mechanism | targeting multiple tumor antigen to avoid tumor antigen |
MoA Biomarker | biomarkers to optimize selection of patients who most likely would benefit from ACT, using combination therap |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists.. Adoptive cell therapies (ACTs) include chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTES), tumor-infiltrating lymphocytes, and T-cell receptor (TCR) gene-modified T-cells. ACTs have significantly improved patient outcomes associated with hematologic malignancie… |
Toxicology CRS | Reported |
Clinical Safety signal | Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists.. Adoptive cell therapies (ACTs) include chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTES), tumor-infiltrating lymphocytes, and T-cell receptor (TCR) gene-modified T-cells. ACTs have significantly improved patient outcomes associated with hematologic malignancie… |
Clinical Selected reported efficacy | ORR 92.9% |
Clinical Reported ORR | 92.9% |
Clinical Result source | ClinicalTrials.gov NCT03310619 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03310619 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Gene Modified T Cells |
Overview Company | Calimmune, Inc. |
Overview Modality | CGT |
Overview Target | Prostate Cancer |
Overview Indication | Colorectal Cancer |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | viral vectors, CAR T cells were produced using the piggyBac transposon system of genetic mod |
MoA Mechanism | targeting multiple tumor antigen to avoid tumor antigen |
MoA Biomarker | biomarkers to optimize selection of patients who most likely would benefit from ACT, using combination therap |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists.. Adoptive cell therapies (ACTs) include chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTES), tumor-infiltrating lymphocytes, and T-cell receptor (TCR) gene-modified T-cells. ACTs have significantly improved patient outcomes associated with hematologic malignancie… |
Toxicology CRS | Reported |
Clinical Safety signal | Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists.. Adoptive cell therapies (ACTs) include chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTES), tumor-infiltrating lymphocytes, and T-cell receptor (TCR) gene-modified T-cells. ACTs have significantly improved patient outcomes associated with hematologic malignancie… |
Clinical Selected reported efficacy | ORR 92.9% |
Clinical Reported ORR | 92.9% |
Clinical Result source | ClinicalTrials.gov NCT03310619 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03310619 |
추천 비교
추천 비교